The validity of giving adjuvant capecitabine after standard anthracycline and/or taxanes based neo-/adjuvant chemotherapy in early triple-negative breast cancer patients: An Egypt - Egyptian Knowledge Bank

253126

The validity of giving adjuvant capecitabine after standard anthracycline and/or taxanes based neo-/adjuvant chemotherapy in early triple-negative breast cancer patients: An Egypt

Article

Last updated: 04 Jan 2025

Overview Similar Items

Article

Pattern of metastasis with breast cancer in Egyptian cancer patients: A single center retrospective study

Article

Long term survival outcome of childhood acute lymphoblastic leukemia treated with modified TXIIIB protocol at South Egypt Cancer Institute

Article

Assessment of Effectiveness of Maintenance Capecitabine among Triple Negative Breast Cancer Patients Attending Suez Canal University Hospital

Article

The role of Her 2 neu and N-cadherin expression in hepatocellular carcinoma

Article

Clinicopathological Characteristics and Survival of Triple-Negative Breast Cancer Patients: A single Institution Study from Egypt

Article

Factors Affecting Shared Decision-Making in Breast Cancer Surgeries: Egyptian Perspective

Article

Added Metformin to Systematic Neoadjuvant Chemotherapy in Breast Cancer Patients: Randomized Study from Egypt

Article

Triple Negative Breast Cancer, Clinicopathologic Study of Egyptian Patients, NCI Experience

Article

PLATINUM BASED VERSUS ANTHRACYCLIN BASED NEOADJUVANT CHEMOTHERAPY IN NONMETASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS

Article

The Outcome of Acute Lymphoblastic Leukemia in Infants at National Cancer Institute Egypt: 10 Years Experience